Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

Exclusion Criteria

• •1. Patient is currently receiving antiviral, immunomodulatory or corticosteroid therapy.
• •2. Patients previously treated with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection.
• •3. Previous treatment with interferon must have ended at least 6 months prior to the screening visit.
• •4. Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
• •5. Patient is co-infected with HCV or HIV.
• •6. Patient has evidence of decompensated cirrhosis or hepatocellular carcinoma (alpha fetoprotein).
• •7. Patient is pregnant or breast-feeding.
• •8. Patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases. For males, condoms should be used. Females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal, or using at least a medically acceptable barrier method of contraception (i.e., IUD, barrier methods with spermicide or abstinence).
• •9. Patient has a clinically relevant history of abuse of alcohol or drugs.
• •10. Patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
• •11. Subjects who are currently participating in another investigational study or has been taking any investigational drug within the last 4 weeks prior to Screening Visit.
• •12. Subjects who are taking any traditional Chinese medication, or has been taking any traditional Chinese medication within the last 2 weeks prior to Screening Visit.
• •13. Any criteria, which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol.